Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases
ASAHI KAISEI CRP UNSP/ADR (AHKSY)
NASDAQ:AMEX Investor Relations:
asahi-kasei.co.jp/asahi/en/ir
Company Research
Source: Business Wire
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma, a global provider of healthcare and pharmaceutical solutions, in collaboration with Alchemedicine, has announced that its novel Endothelin A (ETA) receptor antagonist AK1960 has advanced to a Phase I clinical study following a successful preclinical phase. AK1960 is expected to be used in the treatment of various refractory diseases—medical conditions resistant to standard therapies. The initiation of a Phase I study is considered a significant step toward growing Asahi Kasei’s healthcare impact.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218477883/en/Asahi Kasei's Tokyo HeadquartersAK1960 is a small molecule with a new core structure derived from Alchemedicine’s HiSAP™1 platform. It exhibits high selectivity, potent inhibition for the ETA receptor and has demonstrated efficacy in animal models for kidney diseases. AK1960 is expected to contribute to the treatment of var
Show less
Read more
Impact Snapshot
Event Time:
AHKSY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AHKSY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AHKSY alerts
High impacting ASAHI KAISEI CRP UNSP/ADR news events
Weekly update
A roundup of the hottest topics
AHKSY
News
- MAIA Pharmaceuticals Selected by Asahi Kasei Pharma to Advance Teribone™ for US Osteoporosis Patients [Yahoo! Finance]Yahoo! Finance
- IEEE Recognizes Asahi Kasei Microdevices' Commercialization of Thin-Film Hall Elements as an IEEE Milestone [Yahoo! Finance]Yahoo! Finance
- IEEE Recognizes Asahi Kasei Microdevices’ Commercialization of Thin-Film Hall Elements as an IEEE MilestoneBusiness Wire
- Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases [Yahoo! Finance]Yahoo! Finance
- A Look At Asahi Kasei (TSE:3407) Valuation After Upgraded Earnings Guidance And Rising Net Income [Yahoo! Finance]Yahoo! Finance